"10.1371_journal.pone.0020516","plos one","2011-11-03T00:00:00Z","Ioanna Vallianou; Nikolaos Peroulis; Panayotis Pantazis; Margarita Hadzopoulou-Cladaras","Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece; ADNA Inc., Oklahoma City, Oklahoma, United States of America","Conceived and designed the experiments: IV PP MHC. Performed the experiments: IV NP. Analyzed the data: IV PP MHC. Contributed reagents/materials/analysis tools: PP MHC. Wrote the paper: IV PP MHC.","Dr. Pantazis has served as a consultant at ADNA since 2009. This company (ADNA) is interested only in the development of new anticancer drugs and/or methodologies for the treatment of cancer patients and monitoring the effectiveness of anticancer drugs. A formal agreement has been signed between Dr. Pantazis and ADNA about the duties/responsibilities of Dr. Pantazis solely on projects pertinent to cancer. Therefore, there is no restriction for Dr. Pantazis to share and/or provide non-commercially available materials used in the camphene study. All data presented in this paper are included in a patent application with the title Camphene reduces plasma cholesterol and triglycerides (20110100564). This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","11","Ioanna Vallianou","IV",4,TRUE,3,2,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
